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Lung cancer continues to be a major global health problem;
the disease is diagnosed in more than 1.6 million new pa-
tients each year. However, significant progress is underway
in both the prevention and treatment of lung cancer. Lung
cancer therapy has now emerged as a “role model” for
precision cancer medicine, with several important thera-
peutic breakthroughs occurring during 2015. These ad-
vances have occurred primarily in the immunotherapy field
and in treatments directed against tumors harboring spe-
cific oncogenic drivers. Our knowledge about molecular
mechanisms for oncogene-driven tumors and about resis-
tance to targeted therapies has increased quickly over the
past year. As a result, several regulatory approvals of new
agents that significantly improve survival and quality of life*Corresponding author.
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Ongoing Efforts in Lung Cancer Research and
Treatment
Section Authors: Giorgio V. Scagliotti, MD, PhD, Paul
A. Bunn, Jr., MD, David P. Carbone, MD, PhD, Fred R.
Hirsch, MD, PhD
The decoding of the human cancer genome and
advent of therapies targeting driver mutations represent
two major milestones for the clinical implementation of
precision medicine in patients with lung cancer. This
requires an understanding of cancer genes and muta-
tional processes, as well as an understanding of their
evolution during tumor development and an apprecia-
tion for the genetic heterogeneity among cancer cells.
Ongoing global efforts to systematically search for the
most relevant genetic changes in each subtype of
thoracic cancer will, it is hoped, increase the percentage
of tumors that will respond better to new drugs target-
ing distinct genetic profiles. Many of the genetic alter-
ations can be targeted by oral medications that have
much higher response rates and much lower toxicity
compared with chemotherapy. Although targeted drugs
dramatically improve the outcome of patients with tu-
mors harboring specific alterations, molecular and clin-
ical resistance almost invariably develops. New drugs
specifically active in the resistance setting have now
been developed and, it is hoped, will further contribute
to making lung cancer a chronic disease. Additionally,
the development of rational combinations may further
improve outcomes.
Even more recently, it has become evident that in-
teractions between malignant and neighboring nonma-
lignant cells create a dynamic tumor microenvironment
that can be therapeutically exploited. Important inter-
cellular communications are driven by a complex and
dynamic network of cytokines, chemokines, growth fac-
tors, and inflammatory and matrix remodeling enzymes
against a background of major perturbations in the
physical and chemical properties of lung tumor tissue. A
better understanding of the interaction between cancer
cells and the immune system has already generated
drugs that use the body’s immune system to fight the
cancer. For example, cancer cells often have a protein
called programmed death ligand 1 (PD-L1) on their
surface that helps them evade the immune system. New
drugs that block the PD-L1 protein, or the corresponding
programmed cell death protein 1 (PD-1) protein on im-
mune cells, T cells, can help the immune system recog-
nize the cancer cells and attack them. Although robust
data on these new drugs have already been generated in
the setting of second-line therapy of non–small cell lung
cancer (NSCLC), as discussed in the “Immunotherapy”
section, their role in the front-line and earlier diseasesettings, as well as their combination with existing and
newer targeted therapies, are promising areas of
ongoing clinical research. Future research also needs to
explore new and potentially better predictive assays
than PD-L1 immunohistochemical (IHC) assays for se-
lection of patients to receive immunotherapy.
In this volume of the Journal of Thoracic Oncology, the
International Association for the Study of Lung Cancer
(IASLC) has introduced another valuable educational
resource to keep busy practitioners, scientists, and
others interested in lung cancer up-to-date with the
newest advances in lung cancer, with the primary focus
on NSCLC, as expert leaders in the field and the IASLC
have recently published a separate extensive and up-to-
date review on small cell lung cancer (SCLC) in the
Journal of Thoracic Oncology,1 which the reader is
encouraged to peruse. This current article is meant not
to be an all-encompassing review but to cover the
highlights of the field along with the necessary refer-
ences for further reading. The Editors, Anne Tsao and
Harvey Pass, along with the Managing Editor, Murry
Wynes, are grateful to all of the contributors, who not
only provided superlative commentary but also did so in
an expeditious fashion. We hope that this ongoing annual
series will be a Journal of Thoracic Oncology feature that
you will look forward to, and that it will serve to help
you in the management of your patients or stimulate
provocative questions in the laboratory.
Prevention and Early Detection
Tobacco Control and Lung Cancer Prevention
Section Authors: Graham W. Warren, MD, PhD,
Chunxue Bai, MD, PhD
Tobacco control is essential to preventing lung cancer
and improving outcomes for patients in whom lung
cancer is diagnosed. Comprehensive reviews clearly
demonstrate that combustible tobacco is the primary
causative risk factor for the development of 80% to 90%
of lung cancer in men and women and that smoking
cessation reduces the risk for lung cancer in a time- and
dose-dependent manner.2–4 Among smokers, there are
significantly increased risks for several major cancers,
including lung cancer.5 Smoking not only causes cancer,
but continued smoking alters cancer biology, leading to
tumors that are resistant to cancer treatment and
thereby leading to increases in overall and cancer-
specific mortality.2,6 Examples of proven methods that
reduce the burden of tobacco and lung cancer include
primary prevention of tobacco use in youth, regulation
and taxation of tobacco products, antismoking cam-
paigns and legislation (such as indoor air laws and
smoking bans), and provision of evidence-based smoking
cessation support before and after a diagnosis of
616 Tsao et al Journal of Thoracic Oncology Vol. 11 No. 5cancer.2,4,6,7 Unfortunately, worldwide tobacco control is
highly variable and highly dependent on a complex
interaction between governmental regulation, taxation,
public awareness, social patterns, the tobacco industry,
and people who consume tobacco products.8 In coun-
tries with stronger tobacco control laws, reductions in
lung cancer incidence and mortality lag behind re-
ductions in smoking prevalence by approximately 20
years.2,4 However, tobacco consumption continues to
rise in several developed countries, including the Peo-
ple’s Republic of China, where the health burden caused
by tobacco is also expected to continue to rise.2,9
Fortunately, recent changes in tobacco control in the
People’s Republic of China, such as indoor smoking bans
enacted in Beijing in 2015, are expected to curtail future
adverse health effects of tobacco.
Early diagnosis through screening for lung cancer is a
proven method of reducing mortality,10 and recent data
show that smoking cessation for 7 years had a survival
benefit comparable to that of screening.11 Unfortunately,
recent data from IASLC surveys demonstrate that lack of
resources, training, and time are primary barriers to
providing cessation support.12 However, integrating to-
bacco control and cessation support into the diagnosis
and management of patients with lung cancer does not
have to be difficult and can be tailored to patient- and
institution-specific needs.6,13 Collectively, addressing
tobacco use in conjunction with advances in lung cancer
therapy will provide the greatest benefit to patients and
society.
Lung Cancer Screening
Section Authors: Harry J. de Koning, MD, PhD,
A. Uraujh Yousaf-Khan, MD, Annette McWilliams,
M.B.B.S., FRACP
Status of the NELSON Trial. Lung cancer screening with
low-dose computed tomography (LDCT) is recom-
mended in the United States by the U. S. Preventive
Services Task Force on the basis of the results of the
National Lung Screening Trial (NLST), which showed a
20% reduction in lung cancer mortality and a 6.7%
decrease in all-cause mortality.10,14 In Europe, smaller
underpowered trials showed no significant mortality
reduction.15–17 The largest European trial, the Dutch-
Belgian Randomized Lung Cancer Screening Trial
(NELSON), aimed to determine whether LDCT screening
can reduce lung cancer mortality by at least 25%.18,19
The screened group received LDCT at years 1, 2, 4, and
6.5.20,21 Currently, all rounds have been completed. The
lung cancer detection rate was 3.2% and the number
needed to screen for the detection of lung cancer was 85
to 123 per round.20,22 The final mortality and cost ana-
lyses are expected within 2 years.Technical Contributions of the NELSON Trial.
NELSON utilized a nodule protocol based on volumetric
assessment, nodule growth (defined as a change in volume
of 25%), and volume doubling time (VDT).18,20,21 LDCT
results were defined as follows: (1) negative, screened at
next round (newnodules<50mm3orpreviously detected
nodule with growth <25% or growth 25% and VDT
>600 days); (2) positive, referred to pulmonologist (new
nodules >500 mm3 or previously detected nodule with
growth 25% and VDT <400 days); and (3) indetermi-
nate, referred for a short-term follow-up computed to-
mography (CT) (new nodules 50–500 mm3 or previously
detected nodule with VDT 400–600 days). The use of this
nodule management strategy resulted in a higher positive
predictive value (40.6% versus 3.6%) and a substantially
lower false-positive result (59.4% versus 96.4%) than in
the NLST.10,22,23
Modeling of Risk for Screening Participation and
Management of CT-Detected Pulmonary Nodules.
Selection criteria for LDCT screening have largely been
based on age and smoking history, but screening is most
effective when applied to people at high risk.24,25 The
use of multivariate risk-prediction models to select
participants who will most benefit will likely be the more
cost-effective strategy.24–28 Multiple risk prediction
models exist, but only two are based on large prospec-
tive population-based samples: the Tammemagi pros-
tate, lung, colorectal, and ovarian (PLCO) model and the
Hoggart European Prospective Investigation into Cancer
and Nutrition model.24,29–31 Retrospective analysis has
shown the PLCOm2012 model to be more accurate and
efficient than the NLST/U. S. Preventive Services Task
Force selection criteria.24,28,30 There was an observed
risk threshold at which CT-screened participants had
reduced lung cancer mortality.30 The Pan Canadian Early
Detection of Lung Cancer Study used an earlier version
(PLCOm2008) for recruitment. It was accurate and cost-
effective, with an incremental cost-effectiveness ratio of
$9410 per quality-adjusted life-year compared with
$81,000 per quality-adjusted life-year in the NLST.32–34
LDCT screening frequently detects pulmonary nod-
ules for which there is no universally accepted man-
agement protocol. The only evidence-based lung nodule
risk calculator was published by the Pan Canadian
team.35 It was designed to assist in the management of
nodules when first detected in a screening setting by
using a probabilistic approach.26,35 This calculator has
been validated in two cohorts and has been suggested to
have performance superior to that of the Lung CT
screening reporting and data system classification.36–38
It is recommended by the American College of Radi-
ology Lung CT Screening Reporting and Data System and
the British Thoracic Society Guidelines.39,40
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Tammemagi PLCO29 and the Hoggart European Pro-
spective Investigation into Cancer and Nutrition model31
to select screening participants and the McWilliams
models for nodule triage,35 combined with volumetric
analysis of higher-risk nodules over short-term follow-
up is the likely future direction for a lung cancer
screening program.
Stage I through III NSCLC
Pathology
Section Authors: Ming Sound Tsao, MD, FRCPC,
Prasad S. Adusumilli, MD, FCCP
In 2015, the World Health Organization published the
fourth edition of the Classification of Tumours of the
Lung, Pleura, and Thymus.41,42 The new classification
was developed by an international panel of multidisci-
plinary experts. Compared with the third edition pub-
lished in 1999 and 2004, the new classification included
several important changes: (1) classification applied to
small biopsy and cytologic samples, (2) molecular testing
for treatment selection, (3) inclusion of IHC markers for
more precise classification of NSCLC, (4) changes in the
classification of squamous carcinoma and adenocarci-
noma (ADC), and (5) new genomic information for
various types of lung cancers.
The new World Health Organization classification
for lung ADC was based on the 2011 classification
recommended by the IASLC/American Thoracic
Society/European Respiratory Society.43 Subsequent
to its initial publication, many studies worldwide
have validated the prognostic value of this classifica-
tion.44–61 In particular, the high risk for distant
recurrence in solid predominant lung ADC,53 local or
regional recurrence in lung ADC with a micropapillary
component, and presence of an invasion pattern of
spread through alveolar spaces beyond the edge of the
tumor into the surrounding lung parenchyma, espe-
cially after limited resection, were reported.62–66 In
contrast, ADC with a purely lepidic pattern (ADC in
situ [AIS]) or with an invasive area of 0.5 cm or less
(minimally invasive ADC) are associated with 100%
survival after complete surgical resection.48,57,58
Furthermore, the size of the invasive area in lepidic
predominant ADC appeared to be correlated with
disease-free survival (DFS).57 However, recognition of
the predominant histological subtype in preoperative
small biopsy specimens and on frozen sections re-
mains a challenge.67,68 Importantly, pooled analyses of
retrospectively reclassified lung ADC cases (n ¼ 575)
from four pivotal adjuvant chemotherapy trials by the
Lung Adjuvant Cisplatin Evaluation Biology group
showed significant benefit from adjuvant chemo-
therapy for DFS and specific DFS for patients withmicropapillary and solid predominant tumors, but not
for patients with acinar or papillary predominant tu-
mors (Fig. 1).51
The past few years have also witnessed advances in
deciphering the genetics of lung cancers through
completion of multiplatform genomic profiling studies.
The Cancer Genome Atlas Research Network completed
comprehensive profiling of 500 resected lung squamous
carcinomas and ADCs.69,70 Other groups have reported
multi-omics profiling of other types of lung carcinomas,
including small cell carcinoma.71–78 These, together with
targeted mutation analyses of large numbers of NSCLCs
(Fig. 2),79–81 have advanced lung cancer diagnosis and
treatment in the context of personalized medicine.
Staging
Section Authors: Ramón Rami-Porta, MD, Hisao
Asamura, MD
The seventh edition of the tumor, node, and metas-
tasis (TNM) classification was revised according to the
analyses of the new database of the IASLC. The new
eighth edition includes retrospective data from 73,251
patients and prospective data from 3905 in whom lung
cancer was diagnosed from 1999 to 2010 and registered
in 35 data sources in 16 countries around the world.82
The T, N, and M components of the classification were
analyzed separately.83–85 The recommendations for
changes derived from these analyses are summarized in
Table 1.
The most relevant innovation for the T component is
that tumor size is an important prognostic factor and is
now a descriptor in all T categories. Endobronchial
location less than 2 cm from the carina and total atel-
ectasis/pneumonitis become T2 descriptors, invasion of
the diaphragm becomes T4 as its prognosis is more
similar to this category than to T3, and mediastinal
pleural invasion disappears as a T descriptor because it
is rarely used.85
The categories of the N component remain the same
because they separate groups of tumors with different
prognosis, at both clinical and pathological staging. In
addition, the analyses of survival in patients with path-
ologically staged tumors showed that quantification of
nodal disease according to the number of involved nodal
stations has a prognostic impact.83 Finally, the analyses
of survival of patients with disseminated disease vali-
dated the M1a descriptors and allowed for the separa-
tion of those with a single extrathoracic metastasis
(M1b) from those with multiple extrathoracic metastases
in one or several organs (M1c).84
The recommended changes implied the subdivision
of stage IA, the creation of stage IIIC for T3 and T4 tu-
mors with N3 disease, and the subdivision of stage IV
into stage IVA and IVB to include intrathoracic
Figure 1. Survival curves according to treatment arm (chemotherapy versus observation) in the acinar/papillary (A, C, and E)
and micropapillary/solid (B, D, and F) subgroups for overall (A and B), disease-free (C and D), and specific disease-free
survival (E and F). p Values from log-rank test, hazard ratios (HRs), and 95% confidence intervals (CIs) of treatment ef-
fect, which were estimated through a univariable Cox model stratified on trial, are reported for each subgroup and end point.
Reprinted with permission from Tsao et al.51
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extrathoracic metastases, respectively. Figures 3 and 4
show weighted survival by stage according to the sev-
enth edition of the TNM classification and the newly
proposed eighth edition of TNM stage based on the
entire set of cases available for reclassification.86 These
changes are applicable to SCLC.87 Other recommenda-
tions are the inclusion of AIS in the Tis category and the
utilization of size of the solid/invasive component to
determine the T category for part-solid ADCs.Role of Surgery
Section Authors: Paul E. Van Schil, MD, PhD, Gail E.
Darling, MD, FRCSC
LDCT screening and management of screen-detected
small nodules were dominant themes in 2015, but sur-
gical quality remains an important topic. Lobectomy
with R0 resection and lymph node dissection remains
the accepted standard for treatment of NSCLC against
which all other treatment must be compared.88 However,
sublobar resection appears to provide equivalent
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Figure 2. Frequency of molecular aberrations in various driver oncogenes in lung adenocarcinomas and current available
drugs against these oncogenic proteins. These frequencies are a combination of data from the Lung Cancer Mutation Con-
sortium and frequencies listed in Shea et al.81 Shown in the boxes are the available drugs in addition to their developmental
phase. EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma receptor tyrosine kinase; MET, mesenchymal-to-
epithelial transition factor; HER2, erb-b2 receptor tyrosine kinase 2; ROS1, ROS proto-oncogene 1, receptor tyrosine kinase;
BRAF, B-Raf proto-oncogene, serine/threonine kinase; RET, ret proto-oncogene; NTRK1, neurotrophic tyrosine kinase re-
ceptor type 1; PIK3A, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha; MEK1, mitogen-activate protein
kinase kinase 1; KRAS, Kirsten rat sarcoma viral oncogene homolog.
May 2016 Scientific Advances in Lung Cancer 2015 619survival for ground glass nodules (GGNs) and patients
with limited life expectancy.89–93 Minimally invasive
surgery allows an operation, including lobectomy, to be
offered to those previously considered to be high risk.94
Whether sublobar resection is oncologically equivalent
to lobectomy awaits the results of large randomized
trials (JCOG0802/WJOG4607L and Cancer and Leukemia
Group B 140503).95,96
Pure GGNs are predominantly AIS or minimally
invasive ADC. Resection is required if growth occurs or a
solid component develops. Segmentectomy is acceptable
if the lesion is smaller than 2 cm, the lesion has a posi-
tron emission tomography maximum specific uptake
value less than 2.0, and the results of examination of a
frozen section of hilar and mediastinal nodes are nega-
tive. Ongoing research (JCOG0804/WJOG4507L) will
address management of pure GGNs.10,22,24,27,43,97–108
Stereotactic radiotherapy (SRT) is increasingly being
used to treat NSCLC, but whether it is oncologically
equivalent to an operation remains debated, withconflicting evidence in the literature. A pooled analysis of
two small randomized trials that both closed on account
of poor accrual reported superior overall survival (OS)
with SRT but no difference in recurrence-free survival.
This is critically discussed further in the Advances in
Radiotherapy section.
Management of locally advanced stage IIIA-N2 NSCLC
remains controversial. A systematic review and meta-
analysis found that both surgical and radiotherapy op-
tions were valid in bimodality trials focusing on the
specific role of surgery versus radiotherapy. In trimo-
dality regimens, however, surgical results were found
to be superior, with a 13% relative improvement in
OS.109–117 The general consensus is that patients with
single-station N2 disease found during a surgical proce-
dure should have postoperative chemotherapy and pa-
tients with single-station ipsilateral N2 disease found
during pre-resection invasive staging, in whom R0
resection would be accomplished with a lobectomy,
should be considered for induction chemotherapy.
Table 1. Recommended Changes for the Descriptors and Stages for the Eighth Edition of the TNM Classification for Lung
Cancer
N Categories
Overall Stage
Descriptor in Seventh Edition Proposed T/M N0 N1 N2 N3
T1  1 cm T1a IA1 (IA) IIB (IIA) IIIA IIIB
T1 > 1–2 cm T1b IA2 (IA) IIB (IIA) IIIA IIIB
T1 > 2–3 cm T1c IA3 (IA) IIB (IIA) IIIA IIIB
T2 > 3–4 cm T2a IB IIB (IIA) IIIA IIIB
T2 > 4–5 cm T2b IIA (IB) IIB (IIA) IIIA IIIB
T2 > 5–7 cm T3 IIB (IIA) IIIA (IIB) IIIB (IIIA) IIIC (IIIB)
T3 structures T3 IIB IIIA IIIB (IIIA) IIIC (IIIB)
T3 > 7 cm T4 IIIA (IIB) IIIA IIIB (IIIA) IIIC (IIIB)
T3 diaphragm T4 IIIA (IIB) IIIA IIIB (IIIA) IIIC (IIIB)
T3 endobronchial: location/atelectasis 3–4 cm T2a IB (IIB) IIB (IIIA) IIIA IIIB
T3 endobronchial: location/atelectasis 4–5 cm T2b IIA (IIB) IIB (IIIA) IIIA IIIB
T4 T4 IIIA IIIA IIIB IIIC (IIIB)
M1a M1a IVA (IV) IVA (IV) IVA (IV) IVA (IV)
M1b single lesion M1b IVA (IV) IVA (IV) IVA (IV) IVA (IV)
M1c multiple lesions M1c IVB (IV) IVB (IV) IVB (IV) IVB (IV)
Note: Where there is a change, the resultant stage groupings proposed for the eighth edition are in bold, and the stage in the seventh edition is given in
parenthesis.
TNM, tumor node, and metastasis; T, tumor; M, metastasis.
Reprinted with permission from Goldstraw et al.86
620 Tsao et al Journal of Thoracic Oncology Vol. 11 No. 5Whether radiotherapy should be combined with chemo-
therapy for induction purposes remains controversial and
is discussed in the “Radiotherapy” section of this article.
Resection for patients with oligometastatic disease
represents a relatively new concept in thoracic surgery,
and long-term survival may be obtained when completeFigure 3. Overall survival by clinical stage according to the se
tumor, node, and metastasis (TNM) classification. Groupings use
is weighted by type of database submission: registry versus othresection of the primary and metastasis are performed.
In the upcoming eighth TNM classification a new sub-
category M1b, consisting of patients with a single
metastasis in a single organ, will be introduced. M1c will
be defined as multiple metastases in a single organ or
multiple organs. Further trials are needed to determineventh edition (A) and the proposed eighth edition (B) of the
the entire database available for the eighth edition. Survival
er. Reprinted with permission from Goldstraw et al.86
Figure 4. Overall survival by pathological stage according to the seventh edition (A) and the proposed eighth edition (B).
Groupings use the entire database available for the eighth edition. Survival is weighted by type of database submission:
registry versus other. MST, median survival time; NR, not reached. Reprinted with permission from Goldstraw et al.86
May 2016 Scientific Advances in Lung Cancer 2015 621optimal treatment and long-term follow-up in this pa-
tient population.84,118,119
In conclusion, the role of surgery remains important
in the management of early, locally advanced, and oli-
gometastatic lung cancer. Ongoing research will refine
screening algorithms and the role of surgery in screen-
detected nodules. Minimally invasive surgery allows
safe surgical management for elderly and high-risk pa-
tients. Every patient should be discussed within multi-
disciplinary teams to determine the optimal diagnostic
and therapeutic strategy.
Role of Adjuvant Chemotherapy
Section Authors: Suresh S. Ramalingam, MD, Giorgio
V. Scagliotti, MD, PhD
Cisplatin-based adjuvant chemotherapy is the stan-
dard of care for patients with large tumors (>4 cm) and
lymph node–positive NSCLC after surgical resection.
Adjuvant chemotherapy results in an absolute improve-
ment in the 5-year survival rate of approximately 5% to
15%.120–123 The next generation of clinical trials in the
adjuvant setting can be broadly categorized into three
major thematic areas: (1) integration of targeted ther-
apy, (2) customization of chemotherapy on the basis of
tumor characteristics, and (3) immunotherapy.
Integration of Targeted Therapy. The results of a
phase III trial that evaluated the role of bevacizumab in
patients with early-stage NSCLC were recently reported
(Eastern Cooperative Oncology Group 1505).124 Patients
(N ¼ 1500) with stages IB, II, and IIIA were randomized
after surgery to receive four cycles of cisplatin-basedchemotherapy given alone or in combination with bev-
acizumab. The results were disappointing, with no dif-
ference in OS (hazard ratio [HR] ¼ 0.99, p ¼ 0.93) or DFS
(HR ¼ 0.98, p ¼ 0.75) between the two study arms. The
RADIANT study evaluated the role of adjuvant therapy
with erlotinib, an epidermal growth factor (EGFR) in-
hibitor, after surgery for early-stage disease.125 There
was no improvement in DFS for erlotinib compared with
placebo (HR ¼ 0.90, p ¼ 0.324), although there was a
promising trend toward improved DFS for patients with
activating mutations in EGFR (HR ¼ 0.61, p ¼ 0.039).
Several ongoing studies in Asia are comparing an EGFR
inhibitor to chemotherapy in patients with EGFR-
activating mutations in the adjuvant setting.
Customization of Chemotherapy. Selecting chemo-
therapy on the basis of baseline expression of DNA repair
pathway markers has been a major focus in in-
vestigations.126 A recent study that randomized patients
to receive customized chemotherapy on the basis of
breast cancer 1 expression levels (BRACA1) failed to
meet its primary end point.127 Another study by the
French Intergroup that evaluated customization of
chemotherapy based on excision repair cross-
complementation group 1 (ERCC1) was discontinued on
account of unreliability of the ERCC1 assay.128 The results
of an Italian study (ITACA) that addresses customized
chemotherapy based on thymidylate synthase and ERCC1
levels in the tumor are eagerly awaited.
Immunotherapy. The recent approval of immune
checkpoint inhibitors targeting the PD-1/PD-L1 pathway
622 Tsao et al Journal of Thoracic Oncology Vol. 11 No. 5in patients with advanced stage NSCLC has prompted
studies of these agents in the adjuvant therapy setting.
Phase III studies with several immune checkpoint in-
hibitors have been initiated across the world.
In 2014, the MAGRIT trial, a phase III placebo-
controlled randomized study of melanoma-associated
antigen 3 (MAGE-A3) vaccine in patients with stage IB–
IIIA resected NSCLC who express the MAGE family
member 3 gene (MAGE-A3), failed to meet its first or
second coprimary end points of improving DFS
compared with placebo in the overall group of MAGE-
A3–positive patients or in the group of MAGE-A3–
positive patients who did not receive chemotherapy.129
The trial was still continued to assess the third
coprimary end point of assessing DFS in a gene signa-
ture–positive subpopulation. Unfortunately, the updated
information indicated that the MAGE-A3 vaccine did not
improve survival outcomes and the trial was subse-
quently closed.130
ALCHEMIST Study. The National Clinical Trials Network
in the United States is conducting a large adjuvant
therapy study that individualizes therapy on the basis of
the genomic features of the patient’s tumor (Fig. 5).
Patients with early-stage NSCLC are screened for EGFR
mutations and anaplastic lymphoma receptor tyrosine
kinase gene (ALK) rearrangements after surgery and are
randomized to receive the relevant targeted therapy
versus placebo. A third arm will be introduced for pa-
tients with EGFR and ALK wild type, with randomization
to receive the immune checkpoint inhibitor nivolumabStage IB (>4cm),
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genomic analyses on tumor specimens on all patients.
Ultimately, this will greatly enhance our understanding
of genomic factors that drive recurrence and sensitivity
to adjuvant therapy.
Advances in Radiotherapy
Section Authors: Daniel R. Gomez, MD, Kenneth E.
Rosenzweig, MD
SBRT for Lung Cancer. Multiple retrospective and
phase I–II trials of stereotactic body radiation therapy
(SBRT) have demonstrated excellent local control in
early stage lung cancer.131 To further test its efficacy,
three phase III randomized trials were initiated to
compare SBRT against surgery: the STARS trial, the
ROSEL trial, and ACOSOG Z4099. Unfortunately, all three
trials were closed early on account of poor accrual.
Chang et al.132 reported on the pooled results of the first
two trials. There were 58 patients randomized to receive
either an operation or SBRT, and the median follow-up
time was 40 months. Surprisingly, there was improved
OS at 3 years in the SBRT arm (95% versus 79% with
surgery, p ¼ 0.037). Recurrence-free survival was
similar in both groups. From a surgical viewpoint, this
analysis was flawed by small sample size, short follow-
up period, and lack of histological confirmation of can-
cer. Moreover, in a retrospective propensity-matched
analysis of patients with NSCLC that compared SBRT
and an operation, an operation provided significantly II & IIIA NSCLC
0 PaƟents
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5-year OS was not different in a similar analysis of
high-risk patients treated with SBRT or sublobar
resection.132–135 Needless to say, because of the small
sample size of the Chang study, further trials are needed,
but this work does support SBRT as a viable treatment
option for early-stage NSCLC in patients who refuse an
operation but are resection candidates. Future trials,
possibly with novel designs that would support
increased accrual, are needed to recommend it as
equivalent to the standard of care, which is an operation.
The treatment of central early-stage NSCLC remains a
challenge because of toxicity. At the 2015 American So-
ciety for Therapeutic Radiology and Oncology meeting,
two abstracts on the treatment of these lesions were
presented. NRG Oncology/RTOG 0813136 demonstrated
a 7.2% dose-limiting toxicity for 12 Gy  5, including one
toxic death. A Washington University phase II trial137
demonstrated excellent local control and acceptable
toxicity using a dose of 11 Gy  5.
Locally Advanced NSCLC. A multicenter phase III ran-
domized trial from Europe tested induction chemo-
therapy alone versus induction chemotherapy with
radiation in patients with stage IIIA (N2) NSCLC who
were scheduled to undergo an operation.116 In the 232
patients who were enrolled, the median event-free sur-
vival (12.8 versus 11.6 months) and OS (37 versus 26
months) were slightly, but not significantly, improved
with the addition of preoperative radiation therapy,
suggesting that chemotherapy alone should be used as
preoperative treatment for resectable stage III NSCLC.
Justifiable criticisms, however, have been raised
regarding this trial, including the slow recruitment from
23 centers over 12 years. Moreover, the quality of de-
livery of radiotherapy in such a trial (very slow
recruitment and many centers) is very problematic. In
spite of all its methodological imperfections, the trial did
show a nonsignificant improvement in the trimodality
arm (median OS 37.1 versus 26.2 months) and critics
would argue that the conclusion that radiotherapy does
not add any benefit to these patients is not justified;
rather, the conclusion should be that a larger trial with
modern standardized radiotherapy is warranted.
Advanced Stage
Introduction to Personalized Medicine and
Targeted Therapies
Section Authors: Stefan Zimmermann, MD, Solange
Peters, MD, PhD
Our understanding of NSCLC has evolved from a single
disease entity to a disease comprising genetically and
clinically distinct subgroups.138 Lung ADC in particular
can now be considered a cluster of discrete molecularsubtypes, with most being defined by a single oncogenic
driver alteration (see Fig. 2). These oncogenic alterations
mainly result in a downstream activation of canonical
mitogen-activated protein kinases (MAPKs)/extracellular
signal–regulated kinases or phosphatidylinositol 3 kinase
(PI3K)/protein kinase B cancer pathways, and include
Kirsten rat sarcoma viral oncogene homolog gene (KRAS),
EGFR, B-Raf proto-oncogene, serine/threonine kinase
gene (BRAF), MET proto-oncogene, receptor tyrosine
kinase (MET) exon14, erb-b2 receptor tyrosine kinase 2
gene (ERBB2), neuroblastoma RAS viral (v-ras) oncogene
homolog gene (NRAS), harvey rat sarcoma viral oncogene
homolog (HRAS), mitogen-activated protein kinase
kinase 1 (MEK1), fibroblast growth factor receptor 2 gene
(FGFR2), fibroblast growth factor receptor 3 gene
(FGFR3), andneurotrophic tyrosine kinase receptor type 2
(TrkB) mutations, ROS proto-oncogene 1, receptor tyro-
sine kinase (ROS1), ret proto-oncogene gene (RET), and
neurotrophic tyrosine kinase, receptor, type 1 gene
(NTRK1) fusions, as well as MET and ERBB and FGFR1/2
amplifications, some of which are characterized by an
extremely low prevalence.69,139 Advances in multiplex
genotyping and high-throughput genomic profiling by
next-generation sequencing allow physicians to routinely
gather therapy-relevantmolecular information in a timely
fashion, a condition that is required for true personalized
medicine in the face of a growing list of molecularly tar-
geted drugs.
The transition from empirical to mechanism-based
biomarker-driven therapeutic decisions has had a pro-
found impact on patients’ clinical outcomes. A historical
comparison of patients with EGFR-mutated NSCLC
treated before and after the approval of gefitinib in Japan
demonstrated a doubling of median survival time, 27.2
months versus 13.6 months.140 In the second- and third-
line setting, patients with ALK-positive NSCLC receiving
crizotinib therapy experienced a 1-year survival rate of
70% versus 44% in crizotinib-naive ALK-positive con-
trols.141 The magnitude of benefit is expected to be even
greater in the future thanks to the accessibility of
second- and third-generation agents for the treatment of
patients with EGFR-mutated and ALK-translocated
NSCLC, allowing for multiple lines of targeted therapy
beyond resistance to initial targeted compound.
This initial success has also brought new challenges.
Because many of the known genetically determined
NSCLC subtypes represent small subsets of NSCLC, novel
clinical trial designs are needed. This has recently led to
the development of innovative and complex large um-
brella trials, which can study multiple arms/strategies in
parallel (see the “Master Protocols” section).
Future regulatory approval will have to rely on
single-arm trials using nonclassical “surrogate end
points,” as was the case initially for crizotinib in 2011 for
624 Tsao et al Journal of Thoracic Oncology Vol. 11 No. 5ALK-rearranged NSCLC and osimertinib, which received
U. S. Food and Drug Administration (FDA) approval in
late 2015 for the treatment of patients with EGFR T790M
mutation-positive NSCLC whose disease has progressed
while or after receiving they were EGFR tyrosine kinase
inhibitor (TKI) therapy.142,143
Intrapatient and intratumor heterogeneity add
another layer of complexity, in some cases predicting
acquired resistance mechanisms.144 Although yet to be
validated and achieve regulatory approval, peripheral
blood circulating tumor DNA may provide more accurate
biomarker testing than do tumor biopsy specimens, in
particular in the setting of drug resistance.145
Still, progress has largely lagged behind for some
subgroups of NSCLC, like squamous cell lung cancer,
specific subtypes of ADC, such as KRAS-mutated tumors,
and those without any known targetable alteration.
Lastly, in all NSCLCs and across various solid cancers,
elucidating the ideal timing and sequence of various
lines of targeted therapy, immunotherapy, and chemo-
therapy will remain an ongoing challenge for clinicians.
ALK and ROS1
Section Authors: Sai-Hong Ignatius Ou, MD, PhD,
Thanyanan Reungwetwattana, MD, MSc
In the past year, there have been developments in
understanding the molecular biology and resistance
mechanisms of ALK-positive NSCLC, regulatory approval
of a new IHC assay, and FDA approval of a third ALK
inhibitor. Eight new fusion partners to ALK gene (SOCS5,
CLIP4, BIRC6, DCTN1, SQSTM1, EIF2AK, PPM1B,
PRKAR1A) were reported in ALK-positive NSCLC.146–149
The importance of fusion partners in ALK-positive
NSCLC is demonstrated by evidence that the HELP
domain in echinoderm microtubule associated protein
like 4 (EML4) plays a role in engaging the RAS-MAPK
pathway as a potential resistance mechanism to ALK
inhibitors.150 MAPK, SRC proto-oncogene non-
receptor tyrosine kinase, and EGFR signaling pathways
have also been shown to provide bypass mechanisms to
ALK inhibitors in tumors that do not harbor resistant
ALK mutations.151 On June 15, 2015, the FDA-approved
the Ventana ALK (D5F3) IHC assay (Ventana Medical
Systems, Tucson, AZ) as a companion diagnostic test to
detect ALK rearrangement in NSCLC.152
Alectinib, a second-generation ALK inhibitor, which
has higher intracranial activity than does crizotinib,153
including against leptomeningeal carcinomatosis,154,155
was approved by the FDA for patients with ALK-
positive NSCLC who are refractory to/intolerant of cri-
zotinib.156,157 Sequential use of ALK inhibitors has led to
increased OS, with some ALK-positive patients reaching
an OS of approximately 5 years.158,159 Lorlatinib
(PF06463922), a third-generation ALK/ROS1 inhibitorthat can overcome certain resistant ALK mutations (but
not ALK L1198F), is now in a phase II clinical trial for
patients with ALK-positive and ROS1-positive NSCLC
(ClinicalTrials.gov identifier NCT01970865).160–162 ALK
I1171X and ALK F1174X resistance mutations have dif-
ferential sensitivities to alectinib and ceritinib, which
may determine which one of the two inhibitors to
use.163,164 Other resistant ALK mutations have been re-
ported.165,166 In a case report, Shaw et al.167 recently
reported that C1156Y-L1198F mutations confer resis-
tance to lorlatinib, ceritinib, alectinib, and brigatinib but
resensitize cells to crizotinib. In this analysis, studies of
cocrystal structure indicated that the L1198F mutation
has greater binding to crizotinib that overcomes the
increased kinase activity of C1156Y.167
Four new fusion partners (CLTC, LIMA1, MSN,
TMEM106B) to ROS1 were identified in 2014 and
2015.69,168–170 and the incidences and clinicopathologic
characteristics of patients with ROS1-positive NSCLC
were described in a comprehensive meta-analysis.171
Crizotinib was granted priority review designation for
a supplemental New Drug Application for patients with
advanced metastatic ROS1-positive NSCLC on the basis of
the efficacy results reported from an expanded cohort of
patients with ROS1-positive NSCLC from the original
crizotinib phase I trial.169,172 Retrospective analysis of
crizotinib in ROS1-positive patients confirmed the high
overall response rate to crizotinib.173 Crizotinib was
subsequently approved by the U.S. FDA on March, 11
2016 for the treatment of patients with ROS-1 gene
alteration positive metastatic NSCLC.174 A novel
crizotinib-resistant mutation, ROS1 D2033N, that is
distinct from G2032R175,176 has been discovered in a
patient with ROS1-positive NSCLC.177
EGFR
Section Authors: Pasi A. Jänne, MD, PhD, Tony S.
Mok, MD
Targeting EGFR continues to be an active area of
clinical trials and novel drug development. Two EGFR-
targeted therapies (osimertinib and necitumimab) were
recently approved, and the result of the first ever trial
comparing first- and second- generation EGFR TKI was
presented. The LUX Lung 7 study178 compared afatinib
with gefitinib in 319 treatment-naive patients with
activating EGFR mutations; the primary end points
included progression-free survival (PFS), time to treat-
ment failure, and OS. Sample size was not justified sta-
tistically. The results demonstrated improvement in PFS
(HR ¼ 0.73, 95% confidence interval [CI]: 0.57–0.95, p ¼
0.017); however, the median PFS times were 11.0 and
10.9 months for the afatinib and gefitinib arms, respec-
tively. Tumor response rate was also statistically
different at 70% versus 56%, favoring afatinib. The data
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icities, including skin rash, stomatitis, and diarrhea, were
more common with afatinib. This second-generation TKI
is considered one of the first-line options for EGFR
mutation–positive lung cancer but is unlikely to fill the
role of first-generation EGFR TKIs.
The most common mechanism of acquired resistance
to EGFR TKIs (in w60% of cases) that develops in pa-
tients with EGFR mutations after drug treatment is the
EGFR T790M mutation.179 A mutant-selective EGFR in-
hibitor, osimertinib (AZD9291), is clinically effective in
this patient population and received accelerated approval
by the FDA. The approval was based on the results of two
studies in patients with advanced disease and EGFR
mutations whose disease had progressed while they were
receiving prior systemic therapy, including a prior EGFR
TKI, and whose tumors harbored the EGFR T790M mu-
tation.180 In the 411 patients with EGFR T790M in the
two studies, the confirmed response rate by blinded in-
dependent central review was 59%. The most common
side effects included diarrhea and rash; less than 5 % of
patients experienced grade 3/4 toxicities.
Although EGFR mutations are rare in squamous cell
lung cancer, EGFR expression is common. The anti-
EGFR–directed antibody necitumumab was evaluated in
a phase III clinical trial in combination with cisplatin and
gemcitabine in 1093 patients. Patients treated with the
combination of cisplatin, gemcitabine, and necitumumab
had a prolonged OS (11.5 versus. 9.9 months, HR ¼ 0.84,
95% CI: 0.74–0.96, p < 0.01) and PFS (5.7 versus. 5.5
months, HR ¼ 0.85, 95% CI: 0.74–0.98, p ¼ 0.02)
compared with patients treated with cisplatin/gemcita-
bine alone.181 Patients treated with the necitumumab
combination experienced a higher rate of rash and ace-
neiform dermatitis than did patients treated with
chemotherapy alone. Additionally, for advanced squa-
mous cell carcinoma of the lung, the LUX Lung 8 open-
label, phase III randomized controlled trial (N ¼ 795)
was published; it reported that afatinib improved PFS
(2.6 versus 1.9 months, HR ¼ 0.81, p ¼ 0.0103) and OS
(7.9 versus 6.8 months, HR ¼ 0.81, p ¼ 0.0077) over
erlotinib as second-line treatment for patients.182 Reg-
ulatory submissions to the FDA and European Medicines
Agency have been filed for use of afatinib in patients
with advanced squamous cell lung cancer whose disease
progressed after first-line chemotherapy.183
Other Targets
Section Authors: Heather A. Wakelee, MD, Robert
Pirker, MD
BRAF Mutation. Mutations (most commonly V600E) in
BRAF, a serine-threonine kinase belonging to the RAF
kinase family downstream of KRAS, are estimated to bepresent in 1% to 3% of NSCLC, more commonly in
smokers.184–188 Supporting early case series data,186 the
first prospective trial (BRF113928) reported a response
rate of 40% with dabrafenib in BRAF V600E-mutated
NSCLC.189 The addition of the MEK inhibitor trametinib
increased the overall response rate to 63%,190 Vemur-
afenib is also active.191–194
KRAS Mutation. More common in smokers, KRAS
mutations are present in approximately 20% to 25% of
lung ADCs and 4% of lung squamous cell carci-
nomas.79,195–198 To date, there are no established tar-
geted therapies for KRAS mutations. In randomized
phase II trials, the addition of the MEK inhibitor selu-
metinib to docetaxel improved median survival (9.4
months versus 5.2 month)199 but failed to improve
outcomes when added to erlotinib.200 The combination
of trametinib, a MEK inhibitor, plus either pemetrexed or
docetaxel showed promising activity.201–203 The MET
inhibitor tivantinib plus erlotinib failed in a phase II trial
after initial promise.204,205 Preclinical data support the
use of mammalian target of rapamycin inhibition and
focal adhesion kinase inhibition as potential strate-
gies,196,206 and immune checkpoint inhibitors may be
particularly active. Three major subgroups of KRAS-
mutant ADCs with distinct biology and therapeutic
vulnerabilities have been characterized on the basis of
co-occurring genetic alterations in serine/threonine ki-
nase 11 (liver kinase B1), tumor protein p53, and cyclin-
dependent kinase inhibitor 2A/B.207
RET Rearrangement. RET proto-oncogene (RET) is
estimated to be rearranged in 1% to 2% of patients with
NSCLC,208–210 and is associated with younger age and
light smoking history in some series,210,211 although a
median age of 62 years old and some patients with a
heavy smoking history were reported in a large series
from Europe.212 RET lung cancers have responded well
to pemetrexed,213 cabozantinib,214 and vandeta-
nib.215,216 Preclinical models also support activity with
alectinib, sunitinib, and sorafenib.208,217,218
MET. MET proto-oncogene, receptor tyrosine kinase
(MET) is a tyrosine kinase receptor for hepatocyte
growth factor. Amplification of MET, which is associated
with poor prognosis, is detected in up to 20% of lung
cancer cases,219–223 and various MET inhibitors,
including crizotinib222,224,225 and less so tivantinib, have
shown activity.205,226,227 In the first reports of MET exon
14 splice variants, which are found in approximately 4%
of lung ADCs, striking activity has been reported with
crizotinib as well as with cabozantinib.228 The frequency
of MET exon 14 skipping mutations is especially high
in sarcomatoid carcinoma,229 an uncommon poorly
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poor prognosis.41
NTRK1. Oncogenic high-affinity nerve growth factor re-
ceptor (tropomyocin receptor kinase A) fusion proteins
caused by rearrangements in neurotrophic tyrosine ki-
nase 1 (NTRK1) are a rare oncogenic driver in NSCLC,
with frequencies ranging from less than 1% to 3%
reported in the literature.230,231 Ongoing clinical trials
with tropomyocin receptor kinase inhibitors, including
entrectinib and LOXO-101, are open to patients with
NSCLC as well as to those with other histological di-
agnoses, with initial responses seen.230
Immunotherapy
Section Authors: Julien Mazières, MD, PhD, Julie R.
Brahmer, MD, Fred R. Hirsch MD, PhD
Introduction. Activation of the immune system to treat
cancer has long been investigated, and after decades of
disappointment, the tide has undoubtedly changed in
2015 with the success of recent clinical trials.
Rational. Multiple mechanisms of immune suppression
prevent effective antitumor immunity.232 Antibody
therapies directed against negative immunologic regu-
lators (checkpoints) have thus been developed. Blocking
PD-1 (Fig. 6) and its ligands (PD-L1 and/or PD-L2) re-
stores cytotoxic antitumor T-cell activity and,PD-L1
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Sznol et al.233subsequently, acts as an effective antitumor response. A
number of antibodies that disrupt the PD-1 axis have
entered clinical development. They can be split into two
main categories: those that target PD-1 (nivolumab and
pembrolizumab) and those that target PD-L1 (atezoli-
zumab, durvalumab, and avelumab).
Results from Recent Trials in NSCLC. Nivolumab is the
first anti-PD-1 targeted drug approved for the treat-
ment of pretreated NSCLC. A phase II and two large
phase III studies have been reported this year (for
details on this and the other trials mentioned in this
section, see Table 2). Checkmate 063 tested nivolumab
as a monotherapy for pretreated squamous NSCLC and
showed interesting response and survival rates,234 and
Checkmate 017 was a phase III randomized trial that
compared nivolumab to docetaxel in patients with
pretreated squamous NSCLC. The OS was prolonged
with immunotherapy, and the toxicity profile was much
more favorable.235 CheckMate 057, a trial with a similar
design, was conducted on patients with pretreated
nonsquamous NSCLC and also reported a benefit in
terms of survival.236
Pembrolizumab has recently been approved by the
FDA to treat PD-L1–positive metastatic NSCLC after
failure of platinum-based chemotherapy. A large phase I
trial reported a very promising response rate and du-
rable response.237 A phase III study has been recently
completed and confirmed the results observed withPD-1
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MHC/anƟgen and CD28/B7 interacƟons 
with anƟgen-presenƟng cells
T-cell
receptor
PD-L1
PD-L2
MHC
CD28 B7
ell
FκB
er
PI3K DendriƟc
cell
Shp-2
or PD-L1 
ing Abs PD-L1
? Atezolizumab 1
? Durvalumab 1
death protein 1 (PD-1)/programmed death ligand 1 (PD-L1)
s against PD-1 and PD-L1 are shown in the boxes along with
ajor histocompatibility complex; PD-L2, programmed death
enhancer of activated B cells. Modified with permission from
Table 2. Main Results of Phase II and III Immunotherapy Clinical Trials in NSCLC
Drug Trial Population ORR
Median
OS, mo
ORR
PD-L1–
Negative
ORR
PD-L1–
Positive
Grade 3/4
Side Effects
Nivolumab
(PD-1 inhibitor)
CheckMate 063
phase II
117 patients with
pretreated SCC
14.5% 8.2 14%
(cutoff 5%)
24%
(cutoff 5%)
17%
CheckMate 017
phase III
vs. docetaxel
272 patients with
pretreated
SCC
20%
vs.
9%
9.2
vs.
6
17%
(cutoff 1%)
15%
(cutoff 5%)
16%
(cutoff 10%)
17%
(cutoff 1%)
21%
(cutoff 5%)
19%
(cutoff 10%)
9%
vs.
71%
CheckMate 057
phase III
vs. docetaxel
582 patients with
pretreated
nonsquamous NSCLC
19%
vs.
12%
12.2
vs.
9.4
9%
(cutoff 1%)
10%
(cutoff 5%)
11%
(cutoff 10%)
31%
(cutoff 1%)
36%
(cutoff 5%)
37%
(cutoff 10%)
10.5%
vs.
53.7%
Pembrolizumab
(PD-1 inhibitor)
KEYNOTE 001
phase I
495 patients with NSCLC
(101 in first- line setting,
394 with pretreated
NSCLC)
19.5%
(24.8% first
line)
12 10% 45.2%
(cutoff 50% IC or TC)
9.5%
KEYNOTE 010
phase II/III vs.
Docetaxel
1034 patients with
advanced
NSCLC
(pembro 2 mg vs.
pembro 10 mg vs.
docetaxel)
18%
vs.
18%
vs.
9%
10.4
vs.
12.7
vs.
8.5
Total
18%
vs.
18.5%
vs.
9.3%
Cutoff 50%
30.2%
vs.
29.1%
vs.
7.9%
13%
vs.
16%
vs.
35%
Atezoluzimab
(PD-L1 inhibitor)
POPLAR
phase II
vs. docetaxel239
287 patients with
pretreated NSCLC
NA 12.6
vs.
9.7
8%
(TC0, IC0)
38%
(TC3, IC3)
22%
(TC2/3, IC2/3)
11%
ORR, overall response rate; OS, overall survival; PD-L1, programmed death ligand 1; PD-1, programmed cell death protein 1; SCC, small cell cancer; NSCLC, non–
small cell lung cancer; IC, immune cells; TC, tumor cells; NA, not available.
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with pembrolizumab versus with docetaxel.238
Atezolizumab, an antibody that targets PD-L1,
showed encouraging results in a phase I study, leading
to durable responses in pretreated patients. In a subse-
quent phase II randomized study (POPLAR), in which
pretreated patients were randomized to receive either
atezolizumab or docetaxel, it also showed a benefit in
terms of survival.239 A phase III study of similar design
(the OAK study) was recently completed.
Durvalumab, which also targets PD-L1, has been
tested as monotherapy with durable clinical activity in a
dose escalation study240 and also in combination with
tremelimumab (a cytotoxic T-lymphocyte-associated
protein 4 inhibitor) with promising results.241 Phase II
and III trials are ongoing in metastatic NSCLC (the
ATLANTIC study), in locally advanced NSCLC (the PA-
CIFIC trial), and in an adjuvant setting (the BR31-
IFCT1401 trial).
Active Clinical Trials in NSCLC. Many trials are
currently being conducted in thoracic oncology; there
are trials examining almost all tumor types and tumor
stages. Briefly, PD-1 and PD-L1 inhibitors are currentlybeing tested in advanced NSCLC in the first-line setting
in comparison with chemotherapy in patients selected
on the basis of their PD-L1 expression status, in locally
advanced NSCLC after chemoradiotherapy, and in early-
stage NSCLC in the neoadjuvant or adjuvant setting.
Combination trials are also ongoing in most of the pre-
vious settings.
Toxicity. Targeting immune checkpoints has led to the
emergence of a new form of toxicity.242,243 These auto-
immune side effects are less frequent and less severe
than the toxicities observed with chemotherapy and
essentially concern endocrine glands (hypophysitis and
hypothyroidism), the skin (rash), the gastrointestinal
tract (diarrhea and colitis), the lung (pneumonitis), the
liver (hepatitis), and the kidneys (renal insufficiency).
However, significant patient education and vigilant
oversight are needed to address these autoimmune-
related toxicities quickly to avoid development of se-
vere symptoms.
Predictive Biomarkers. Not all patients with advanced
NSCLC benefit from these drugs. It is necessary to
improve the selection of patients in this era of
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aforementioned recent trials, PD-L1 expression can be
used to identify good responders and long-term survi-
vors (for details see Table 2). Despite the fact that the
PD-L1 IHC assay seems to be a good predictive assay,
PD-L1 expression is not yet a perfect test. Many ques-
tions are still unresolved concerning the best antibody,
the right cutoff for positivity versus negativity, the
relevance of PD-L1 expression on immune cells versus
tumor cells, and the heterogeneity of PD-L1 expres-
sion.244–246 An academic effort is being conducted by
IASLC, together with pharmaceutical and diagnostic
companies, to optimize and homogenize this test.244,245
Other potential molecular biomarkers under investiga-
tion, such as nonsynonymous mutation burden, could
also be used to help select the best candidates for
therapy.247
Future Efforts. Immunotherapy is an important
advancement in the treatment of advanced pretreated
NSCLC and is a new standard of care for second-line
treatment of NSCLC. Future research initiatives to
improve clinical outcomes are the (1) introduction of im-
munotherapies into the first-line setting for patients with
advanced disease as clinical trials are ongoing and results
should be released over the next 1 to 2 years; (2) use of
immunotherapies during earlier stages of NSCLC (stages I–
IIIA); (3) extension of indications toward other thoracic
malignancies such as SCLC, mesothelioma, and thymic
carcinoma; (4) combination of immunotherapy with stan-
dard therapies; (5) combination of checkpoint inhibitors
(inhibitors of PD-L1/PD-1) with other immunotherapy
inhibitors (inhibitorsof cytotoxicT-lymphocyte-associated
protein 4 and killer cell immunoglobulin-like receptors);
(6) combination of immunotherapy with targeted ther-
apy to combine the good response rate of targeted ther-
apy in selected patients and the durable effects of
immunotherapy; and (7) translational studies to opti-
mize predictive biomarkers, such as PD-L1 expres-
sion245,246 or other markers developed through DNA/
RNA sequencing.
Specific Future Perspectives
Master Protocols
Section Authors: Yang Zhou, PhD, MPH, Roy S.
Herbst, MD, PhD, Vassiliki A. Papadimitrakopoulou,
MD, Mary W. Redman, PhD, David R. Gandara, MD,
Fred R. Hirsch, MD, PhD
The development of a new cancer therapy from the
initial stages of discovery to regulatory approval is a com-
plex and expensive process that can take more than a
decade. Clinical trials face many challenges, including
lengthy start-up time, high upfront expense, and inability to
recruit an adequate number of participants in a timelymanner. This process is particularly difficult when
attempting to develop targeted therapies for rare genotype
subtypes of lung cancer.With this inmind,modernizing the
clinical trials process to keep up with the molecular age by
using innovative approaches and new trial designs is of
high importance. The research community, along with
government and patient advocates, have risen to the chal-
lenge to create “master protocols” that can screen large
numbers of patients and then simultaneously test multiple
new drugs or combinations, with resultant efficiencies in
patient recruitment and regulatory approval.248
In the advanced metastatic stage, one of the first
master protocols to have been developed is the Lung-MAP
(S1400) study for previously treated squamous cell lung
cancer. Lung-MAP is a registration-intent umbrella trial
that simultaneously evaluates multiple treatments
through a series of genotypically driven phase II/III sub-
studies, with “rolling” opening and closing so that each
functions in an independent manner. The current schema
for Lung-MAP is shown in Figure 7. The project is a unique
public-private partnership led by SWOG (formerly the
Southwest Oncology Group) together with the National
Cancer Institute and its National Cancer Trials Network,
the Friends of Cancer Research, and the Foundation of the
National Institutes of Health.249,250
This master protocol provides a mechanism to
genomically test a large population of patients with
squamous lung cancer for genetic alterations. Although
most of the substudies evaluate therapies specifically
targeted at the particular alteration found in a specimen
of a patient’s tumor, patients who do not have one of the
genetic alterations currently being studied are assigned
to a “nonmatch” substudy. Lung-MAP was first launched
on June 16, 2014, and has undergone several protocol
amendments to address the evolving therapeutic land-
scape and the emergence of immunotherapy as one of
the prime treatment modalities for NSCLC.
An example of a master protocol in the early-stage
setting, the ALCHEMIST (see Fig. 5) trial, which was
described previously in the “Role of Adjuvant Therapy”
section, randomizes patients with resected stage IB–IIIA
NSCLC with EGFR mutations or ALK translocations to
receive either placebo or adjuvant erlotinib or crizotinib,
respectively. The duration of administration of the adju-
vant targeted therapy treatment or placebo is 2 years.
Quality and Value of Therapy
Section Authors: Ronan J. Kelly, MD, MBA, David R.
Gandara, MD, Fred R. Hirsch MD, PhD
In 2013, the Institute of Medicine declared the cancer
treatment delivery system in the United States to be a
system in crisis and proposed a conceptual framework to
improve the quality of care.251,252 A key recommenda-
tion was that continuous quality measurement and
Nivolumab/
Ipilimumab
Single Arm
Phase II
Randomized 
Phase III
Biomarker-Driven 
Sub-Studies
Non-Match
Sub-Study
S1400I
Checkpoint 
Naive
GDC-0032 
vs. TBD
S1400B
PI3K +
GDC-0032
Palbociclib
vs. TBD
S1400C
CCGA +
Palbociclib
NivolumabAZD4547
vs. TBD
AZD4547
S1400D
FGFR +
Figure 7. Schema of the Lung-MAP (S1400) study. Biomarker-driven substudies will progress to phase III if the study meets its
end point and a phase III is feasible, at which point the standard of care arm will be determined. TBD, to be determined;
PI3K, phosphatidylinositol-4,5-bisphosphate 3-kinase positive; CCGA, cell cycle gene alteration positive; FGFR, fibroblast
growth factor receptor positive.
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day-to-day oncology practice. An earlier report from the
National Quality Forum identified a lack of available
outcomes versus process metrics in addition to the dif-
ficulties of collecting and managing data as fundamental
weaknesses.253 The widespread adoption of electronic
medical records both in the United States and overseas
means that we now have the ability to adequately mea-
sure the adoption and utilization of key quality metrics.
The high cost of recently approved drugs for lung cancer
has heightened the importance of value as a consider-
ation in treatment decisions and has placed lung cancer
at the center of emerging and evolving paradigms of care
delivery.254
In 2015, we saw a number of innovative efforts
from the American Society of Clinical Oncology, Eu-
ropean Society for Medical Oncology, and National
Comprehensive Cancer Network to address escalating
and unsustainable drug costs with credible data-
driven analyses.255,256 These initiatives allied with
the introduction of the Medicare Access and Chip
Reauthorization Act mean that not only has the cost-
benefit debate finally come of age, but that physi-
cians will increasingly be held responsible for quality
of care and cost control in the years ahead. The
management of lung cancer is no exception. Given the
number of drugs that are now available to the treating
oncologist, as well as the incidence and demographics
of thoracic tumors, it is likely that significant treat-
ment changes will be required if we are to comply
with federally mandated initiatives such as pathway-
directed treatment, episodic bundled payments, and
merit-based incentive payment schemes. As a result,
the IASLC has formed a quality and value task forceand has partnered with the American Society of Clin-
ical Oncology to jointly develop lung cancer treatment
quality measures. The IASLC will continue to lead
transformative efforts in the management of lung
cancer as we look to achieve value-based health care
both in the United States and internationally.
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